Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit http://www.angiotech.com.
Note on Forward Looking Statements:
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the
words "believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities laws. All
such statements are made pursuant to the "safe harbor" provisions of
applicable securities legislation. Forward looking statements may involve,
but are not limited to, comments with respect to our objectives and
priorities for the second half of 2008 and beyond, and our strategies or
future actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research development and
product and drug development. Such forward looking statements involve known
and unknown risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved